ID
45979
Description
Principal Investigator: Ellen L. Goode, Mayo Clinic, Rochester, MN, USA MeSH: Cystadenocarcinoma, Serous,Ovarian Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000897 Twenty five patients with early stage carcinoma (Stage I and II) of the ovary were consented for this study. As part of a collaborative agreement with Illumina Inc, Tumor-DNA and patient matched normal DNA from blood underwent whole genome sequencing and microarray genotyping and RNA underwent RNASeq. Tissue also underwent IHC staining for TP53 mutations. The aim of the study was to profile the genomic landscape of these early tumors to discover biomarkers for early detection or subgrouping into different genomic or outcome subgroups. Analyses performed include somatic mutation analysis, RNASeq mutation analysis, LOH analysis, structural variant detection. The current release of this study focusses on 17 patients with serous carcinoma and stage 1 or 2 and with high grade (3 or 4).
Lien
Mots-clés
Versions (1)
- 02/04/2024 02/04/2024 - Madita Rudolph
Détendeur de droits
Ellen L. Goode, Mayo Clinic, Rochester, MN, USA
Téléchargé le
2 avril 2024
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs000897 Mayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Subject ID, sample ID, and sample use variable obtained from participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Subject ID, age, clinical trial, tumor characteristics including ascites status, CA125 measurement, tumor stage and grade, malignancy, tumor morphology, remission, cytology, recurrence, residual tumor, pathological review, tumor site, cause of death, diagnostic, chemotherapy, and surgery of participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status, and histological type of sample obtained from participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Subject ID, sample ID, and sample use variable obtained from participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Subject ID, age, clinical trial, tumor characteristics including ascites status, CA125 measurement, tumor stage and grade, malignancy, tumor morphology, remission, cytology, recurrence, residual tumor, pathological review, tumor site, cause of death, diagnostic, chemotherapy, and surgery of participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status, and histological type of sample obtained from participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
C0680251 (UMLS CUI [1,2])
C1706256 (UMLS CUI [1,2])
C0029925 (UMLS CUI [1,3])
C0680251 (UMLS CUI [2,1])
C0241889 (UMLS CUI [2,2])
C1511022 (UMLS CUI [2,3])
C1511024 (UMLS CUI [2,4])
C0206530 (UMLS CUI [2,5])
C0006826 (UMLS CUI [1,2])
C0440743 (UMLS CUI [1,3])
C0019638 (UMLS CUI [1,4])